CABA250117C2500
- 0.25
- -0.10-28.57%
Cabaletta Bio Newsroom
Wells Fargo Downgrades Cabaletta Bio(CABA.US) to Hold Rating, Cuts Target Price to $6
Evercore Initiates Cabaletta Bio(CABA.US) With Hold Rating, Announces Target Price $6
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
BofA Securities Cuts Price Target on Cabaletta Bio to $29 From $31, Keeps Neutral Rating
Cabaletta Bio Cut to In-Line From Outperform by Evercore ISI Group
Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Cabaletta Bio Analyst Ratings
Wells Fargo Downgrades Cabaletta Bio to Equalweight From Overweight, Cuts Price Target to $6 From $12
Peering Into Cabaletta Bio's Recent Short Interest
Cabaletta Bio, Inc.'s (NASDAQ:CABA) Latest 25% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Top Premarket Gainers
Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; Cabaletta Bio to Advance, Super Micro Computer to Decline
12 Health Care Stocks Moving In Friday's Pre-Market Session
Express News | Cabaletta Bio Shares Resume Trade
Express News | Cabaletta Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Up 30.2%
Cabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Cabaletta Bio Reports Q3 2024 Financial Results
Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients